Cargando…
Serum exosomal and serum glypican-1 are associated with early recurrence of pancreatic ductal adenocarcinoma
BACKGROUND: The diagnostic performance and prognostic value of serum exosomal glypican 1 (GPC-1) in pancreatic ductal adenocarcinoma (PDAC) remain controversial. In this study, we detected serum exosomal GPC-1 using enzyme-linked immunosorbent assay (ELISA) and determined whether it serves as a pred...
Autores principales: | Zhao, Juan, Guo, Madi, Song, Yushuai, Liu, Shan, Liao, Ran, Zhang, Yu, Zhang, Yumin, Yang, Qi, Gu, Yuanlong, Huang, Xiaoyi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9614098/ https://www.ncbi.nlm.nih.gov/pubmed/36313694 http://dx.doi.org/10.3389/fonc.2022.992929 |
Ejemplares similares
-
High levels of serum glypican‐1 indicate poor prognosis in pancreatic ductal adenocarcinoma
por: Zhou, Cong‐ya, et al.
Publicado: (2018) -
Serum Biomarker Panel for Diagnosis and Prognosis of Pancreatic Ductal Adenocarcinomas
por: Mehta, Shreya, et al.
Publicado: (2021) -
Corrigendum: Serum Biomarker Panel for Diagnosis and Prognosis of Pancreatic Ductal Adenocarcinomas
por: Mehta, Shreya, et al.
Publicado: (2021) -
GREM1 is a novel serum diagnostic marker and potential therapeutic target for pancreatic ductal adenocarcinoma
por: Yang, Sen, et al.
Publicado: (2022) -
Serum Exosomal miRNA-1226 as Potential Biomarker of Pancreatic Ductal Adenocarcinoma
por: Wang, Cheng, et al.
Publicado: (2021)